Clinical trial
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With…
NCT00084656 · Bristol-Myers Squibb, Industry · Completed
Key facts
| NCT number | NCT00084656 |
|---|---|
| Title | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma |
| Official title | An Extended Dosing, Two-phase Study of MDX-010 as Monotherapy or in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 VG in the Treatment of Subjects With Resected Stage III or Stage IV Melanoma |
| Lead sponsor | Bristol-Myers Squibb, Industry |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intraocular Melanoma, Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | ipilimumab, Tyrosinase/gp100/MART-1 Peptides |
| Enrollment | 77 |
| Start date | May 31, 2004 |
| Primary completion | Oct 31, 2009 |
| Completion | Oct 31, 2009 |
| First posted | Jun 11, 2004 |
| Last update posted | Apr 14, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: